INTRODUCTION {#S0001}
============

The genus *Staphylococcus* includes pathogenic organisms in which *Staphylococcus aureus* is the most important. It has overcome most of the therapeutic agents that have been developed against it in the recent years ([@CIT0001]). The introduction of beta-lactamase resistant semi-synthetic penicillins in the early 1960\'s provided temporary relief which ended with the emergence of Methicillin (oxacillin) Resistant *Staphylococcus aureus* (MRSA), discovered shortly after methicillin became available for clinical use ([@CIT0002]).

Many of these MRSA isolates are becoming multidrug resistant and are susceptible only to glycopeptide antibiotics such as vancomycin. Low level resistance even to vancomycin is emerging at present ([@CIT0001]). Prolonged hospital stays, indiscriminate use of antibiotics, lack of awareness, and receipt of antibiotics before coming to the hospital are some of the possible predisposing factors of MRSA emergence. The knowledge of MRSA prevalence and the current antimicrobial profile is necessary in selection of appropriate empirical treatment of these infections. Control of MRSA in hospitals is essential. This can be achieved by proper implementation of hospital infection control measures and regular surveillance activity. Therefore, we planned this study to determine the current antimicrobial profile of MRSA isolates from our hospital so as to formulate an appropriate as well as cost effective empirical therapy.

MATETIALS AND METHODS {#S0002}
=====================

The study was conducted over a one-year (January 2009--December 2009) period at the Department of Microbiology, Army Medical College, National University of Sciences and Technology, Pakistan. All Staphylococcus aureus isolates encountered in routine clinical specimens received from clinical wards of Military Hospital Rawalpindi were identified morphologically and biochemically by standard laboratory procedures including tube coagulase test and DNase test using DNase agar (Oxoid Ltd, Basingstoke, Hampshire, England). MRSA screening was performed on Mueller-Hinton agar using 6 µg oxacillin and 30 µg cefoxitin discs as per Clinical and Laboratory Standards Institute (CLSI) guidelines ([@CIT0003]). Susceptibility to antimicrobial agents was determined by the modified Kirby Bauer disc diffusion method using following antimicrobial discs: vancomycin (30 µg), linezolid (30 µg), teicoplanin (30µg), tigecycline (30 µg), tetracycline (30 µg), minocycline (30 µg), quinopristin/dalfopristin (15 µg), Fluoroquinolones (ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin 5 µg), chloramphenicol (30 µg), rifampicin (5 µg), fusidic acid (10 µg), macrolides (erythromycin and clindamycin 15 µg) as per CLSI guidelines ([@CIT0003]).

RESULTS {#S0003}
=======

A total of 139 MRSA were isolated during the study period. All of the isolated MRSA were found to be susceptible to vancomycin, linezolid and quinopristin/ dalfoprisitin. One hundred and thirty isolates (94%) were susceptible to teicoplanin and minocycline, whereas 93% of isolates were sensitive to chloramphenicol and 91% were sensitive to tigecycline. Only 38 and 22% of the isolates were susceptible to fluoroquinolones and macrolides respectively ([Table 1](#T0001){ref-type="table"}). Majority of MRSA were isolated from pus samples followed by nasobronchial lavages samples ([Fig. 1](#F0001){ref-type="fig"}).
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###### 

Susceptibility pattern of MRSA against various antibiotics.

  Antibiotic                       Sensitive   Resistant   \% sensitive
  -------------------------------- ----------- ----------- --------------
  Vancomycin                       139         0           100
  Linezolid                        139         0           100
  Quinopristin/Dalfopristin        139         0           100
  Teicoplanin                      130         9           94
  Minocycline                      130         9           94
  Chloramphenicol                  129         10          93
  Tigecycline                      127         12          91
  Trimethoprim/sulphamethoxazole   94          45          67
  Fusidic acid                     91          48          65
  Tetracycline                     89          50          64
  Rifampicin                       86          53          62
  Doxycycline                      57          82          41
  Fluoroquinolones                 53          86          38
  Macrolides                       31          108         22

DISCUSSION {#S0004}
==========

A study conducted at the Armed Forces Institute of Pathology Rawalpindi in 2003--2004 indicated that there was no reduced susceptibility of vancomycin against studied MRSA isolates as indicated in our study. However, VISA strains were detected in 4% of isolates in Lahore in 2004 ([@CIT0004], [@CIT0005]). The incidence of VISA in the regional countries has been documented as 3.3% (Srinagar, Kashmir, 2003), 6% (India, 2007) and 7.5% (Iran, 2008) ([@CIT0006]--[@CIT0008]).

The results of our study are in accordance with a study carried out at Aga Khan University in 2009 which showed variable susceptibility pattern with high resistance rates to tetracycline (82%), clindamycin (79%), cotrimoxazole (59%), and rifampicin (50%). Resistance to chloramphenicol (10%) and fusidic acid (9%) was low ([@CIT0009]). A study carried out at Lahore in 2009 showed that only 4% of MRSA isolates were sensitive to fluoroquinoles, whereas 38% of isolates were found to be sensitive in our study ([@CIT0010]).

In our study 100% of the isolates were sensitive to linezolid which is complemented by a 2009 study carried out in Iran. In that study, tigecycline was also found to be 100% which is similar to the results of another study in Iran ([@CIT0011]).

Vancomycin and linezolid are highly effective against MRSA. Chloramphenicol and Minocycline also have good *in vitro* efficacy. Tigecycline, though effective, enhances health care costs enormously.

Effective antimicrobial activity as well as cost effectiveness should be considered in drugs prescribed for MRSA infections. Oral dosing options for linezolid and chloramphenicol can allow earlier discharge of hospitalized patients and minimize the chances of VRSA emergence. Good hospital infection control measures prove to be the main stay against these infections because antibiotics can never be an effective alternative to good medical practice
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